This is a prospective observational phase IV study of a novel, replication-deficient smallpox vaccine that has been recently been approved by FDA. The purpose of this study is to determine if there are any abnormalities detected by electrocardiographic testing and/or blood tests within 35 days of receiving the second dose of smallpox vaccine either alone or co-administered with other vaccines that may/may not be suggestive of myopericarditis.

开始日期2029-03-01

申办/合作机构

Womack Army Medical Center

[+1]

NCT07199569

/ Recruiting临床2期

A Randomized, Double-blind, Phase 2b Comparability Trial in Adults 18 to 49 Years of Age to Assess Immunogenicity, Safety, and Reactogenicity of the MVA-BN Vaccine Manufactured in Different Production Cells

andomized, double-blind, phase 2b trial to assess comparability in immunogenicity, safety, and reactogenicity of MVA-BN vaccine manufactured in primary chicken
embryo fibroblast (CEF) cells and the CCX.E10 quail cell line in adults

开始日期2025-10-27

申办/合作机构

Bavarian Nordic A/S

[+1]

NCT06844487

/ Recruiting临床3期IIT

Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in the Democratic Republic of the Congo

This Phase 3 double-blinded, randomized study aims to evaluate the safety and immunogenicity of the two-dose MVA-BN mpox vaccine regimen, administered subcutaneously, in infants and children aged 4 to 24 months in the Democratic Republic of the Congo (DRC), a population at high risk of mpox infection and complications. The study will compare the safety and immunogenicity of a full-dose regimen versus a half-dose regimen in this population. A hierarchical testing strategy will be applied as follows: first, non-inferiority of the full-dose regimen in infants/children (4-24 months old) will be evaluated against the full-dose regimen in adults from the POX-MVA-045 study. If non-inferiority is demonstrated, the immunogenicity of the half dose in infants/children (4-24 months old) will subsequently be tested for non-inferiority vs the full dose in adult. The trial will be conducted in Boende, Tshuapa Province, DRC.
The trial plans to enroll 344 male and female infants/children, who will be randomized to receive two doses of the MVA-BN vaccine administered 28 days apart. Participants in Child Group 1 (N=172) will receive the standard vaccine dose (0.5 mL), while those in Child Group 2 (N=172) will receive half the standard dose (0.25 mL), with both groups following the same dosing schedule.
This study builds on positive safety and immunogenicity data from prior trials that support the use of the standard dose regimen in younger children. However, considering the developmental differences in the immune systems of infants and young children/adolescents, it aims to evaluate whether a half-dose regimen can provide similar immunogenicity while potentially reducing reactogenicity. The findings will offer valuable insights into the optimal dosing strategy for this age group, balancing safety and immunogenicity to inform future vaccination recommendations.

开始日期2025-05-29

申办/合作机构

University of Antwerp

[+5]

100 项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的临床结果

登录后查看更多信息

100 项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的转化医学

登录后查看更多信息

100 项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的专利（医药）

登录后查看更多信息

157

项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的文献（医药）

2026-03-01·REVIEWS IN MEDICAL VIROLOGY

From Surge to Stability: Navigating MPOX Epidemics Across the Globe With Genomic Insights, Paving the Way for Effective Management Plan

Review

作者: Shahzad, Muhammad ; Malik, Tooba ; Akhtar, Tasleem

ABSTRACT:

MPOX has been declared endemic in Central Africa by WHO in 2017. More recently (2018–2021), MPOX cases have been reported in various regions (endemic as well as non‐endemic) all over the world. The sudden, unexpected and simultaneously emerging cases at geographically disparate areas indicate the probable undetected transmission pattern of the disease. The double stranded DNA virus has evolved over the time into multiple sub‐lineages. Clade I MPXV variant is considered to be more virulent as compared to clade II variety. Mutations in certain sub‐lineages may alter transmission routes, potentially shifting from direct contact to airborne transmission. The clinical presentation involves an incubation phase of 7–9 days, during this phase extensive viral dissemination occurs into the neighbouring cells causing systemic inflammation. The viral prodrome comprising of fever, malaise and myalgias may or may not precede the cutaneous eruptions that evolve over a period of 1–2 weeks, followed by desquamation and scabbing. Treatments include antiviral agents such as tecovirimat, bocindofovir and cidofovir in addition to standard supportive therapy for severe cases or immunocompromised patients. Vaccines such as ACAM2000, JYNNEOS and LC16m8 are available, although they are linked with some risks such as myopericarditis in certain patients. Ongoing global spread and virus mutations highlight the urgent need to accelerate research focused on early MPOX detection, novel treatment options and prevention in order to properly handle potential long‐term challenges such as drug‐resistant strains and future outbreaks. Prioritising the development of targeted, efficient, and less resistance‐prone anti‐MPOX medicines and rapid response systems for effective MPOX management.

2026-02-02·Open Forum Infectious Diseases

Persistent Immunity From Historic Smallpox Vaccination and Its Limited Cross-Neutralization of Monkeypox Virus: A Population-based Serological Study in Taiwan

Article

作者: Fang, Wen-Hui ; Chen, Yen-Chen ; Chen, An-Yu ; Huang, Chih-Heng ; Lin, Le-Tien ; Hung, Yi-Jen

Abstract:

Background:

Understanding the extent of cross-protection conferred by the historic smallpox vaccination and the immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) after the 2022 global mpox outbreak is essential to inform current prevention strategies. In this study, we assessed the seropositivity and neutralizing capacities of the vaccinia virus (VACV)- and monkeypox virus (MPXV)-specific antibodies in 260 Taiwanese individuals.

Methods:

We analyzed serum samples from 260 individuals in Taiwan, stratified by their birth year, before or after 1979, the year of smallpox vaccination cessation. ELISA and plaque reduction neutralization tests were conducted to assess VACV- and MPXV-specific antibody responses. Furthermore, we evaluated an additional cohort of MVA-BN vaccines (n = 9) before and after vaccination.

Results:

Over 80% of individuals born before 1979 retained VACV-reactive antibodies, with 84% of this seropositive subgroup exhibiting neutralizing activity. We detected cross-reactive MPXV antibodies in 69% of individuals who were VACV-seropositive; however, only 65% had MPXV-neutralizing capacity, with titers significantly lower than those against VACV. MVA-BN vaccination enhanced VACV and MPXV antibody levels; however, MPXV-neutralizing titers remained low, particularly in individuals without prior smallpox immunization.

Conclusions:

Historical smallpox vaccination induces long-lasting humoral immunity, and a correlation between VACV and MPXV antibody levels further suggests that it provides some degree of cross-protection against MPXV infection. MVA-BN boosted orthopoxvirus immunity; however, it may be limited in MPXV neutralization in vaccine-naïve populations. These findings offer useful insights for future mpox vaccination strategies and public health planning in regions with varying smallpox vaccination histories.

2026-02-01·Infectious disorders drug targets

A Mini Review on Monkey-Pox: Outbreak, Challenges, and Management Strategies

Article

作者: Ushir, Yogesh V ; Singh, Sudarshan ; Thorat, Dipak S. ; Nagime, Pooja V

Monkeypox (Mpox) has become a significant global health concern, particularly since 2022. It has spread rapidly to numerous locations, and we urgently need to learn more about it. This overview discusses what Mpox is, how it spreads, its effects on people, and the medications that can be used to assist. Between January 2022 and March 2025, approximately 129,523 people were infected with Mpox in 120 countries. This demonstrates that HPV has progressed from being passed down from animals to being transmitted between people, including through intimate touch, as in some sexual interactions. Scientists discovered significant alterations in the virus that could help it adapt to people. Currently, we do not have many therapy alternatives. However, certain medications, such as tecovirimat and cidofovir, as well as specific vaccines (such as MVA-BN), can aid in recovery. When administered promptly after exposure, the vaccine is extremely effective in protecting people. This review emphasizes the importance of detecting Mpox early, monitoring the virus's evolution, and ensuring that people, particularly those who are more susceptible to illness, are immunized. A One Health strategy, which encompasses the care of humans, animals, and the environment in a unified approach, is crucial to preventing future outbreaks. To keep everyone safe, we must prepare for and strengthen our response to Mpox.

408

项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的新闻（医药）

2026-03-27

·BioSpace

Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years

Submission based on topline data from clinical study, demonstrating a comparable safety pro a non-inferior immune response for MVA-BN in children aged 2-11 years compared to adults. COPENHAGEN, Denmark, March 27, 2026 – Bavarian Nordic A/S (OMX: BAVA) has submitted clinical data to the European Medicines Agency (EMA) to support the extension of the MVA-BN ® mpox and smallpox vaccine indication to include children aged 2 to 11 years. The submission is based on positive topline results from a Phase 2 clinical study ( NCT06549530 ) in 227 children aged 2-11 years and 224 adults demonstrating non-inferiority of the immune responses as well as a similar safety profile, between both age groups after vaccination with two standard doses of the MVA-BN vaccine. The study was co-funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and was conducted at sites in the Democratic Republic of Congo (DRC) and Uganda. Both countries reported cases of mpox in adults and children during the recent outbreak across Africa and the world. Following review of the data by EMA, the Marketing Authorisation for MVA-BN could be extended to include use of the vaccine for individuals from 2 years of age later in 2026. “The submission of data for children aged 2-11 years to EMA marks another leap in the advancement of our MVA‑BN vaccine to protect populations broadly against mpox and smallpox,” said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic. “While the risk of mpox in Africa is now more moderate, children remain disproportionally affected by the disease, highlighting the importance to broaden the access to vaccines and therapies for this vulnerable population. Our collaboration with CEPI and local partners in Africa has been instrumental in generating the data to support this submission, and together we continue our endeavors to ensure access to the vaccine for other vulnerable populations.” Dr Kristine Rose, Mpox Disease Programme Lead at CEPI , said: “ Children have been significantly impacted during recent global outbreaks of mpox, with many facing a higher risk of severe disease compared to adults - especially when other health challenges, such as malnutrition, malaria or HIV, are present. This has led to ongoing suffering in the younger populations and continued transmission of the virus, underscoring the need to expand access to vaccines specifically for this age group. Bavarian Nordic’s submission to a WHO listed Authority like the EMA is an important step towards protecting children around the world as, following potential expansion of the vaccine to younger demographics, other regulators could follow suit. ” Professor Hypolite Muhindo Mavoko, University of Kinshasa, principal investigator of the study , said: “In the Democratic Republic of the Congo, children aged 2 to under 12 years represent nearly one-third of the population and are disproportionately affected by mpox complications. Because children interact closely with one another and within households, they can also contribute to ongoing transmission. Expanding vaccine access to this age group is therefore an important step to better protect vulnerable populations and strengthen outbreak control, while reducing the health and economic burden associated with mpox.” About the mpox/smallpox vaccine MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore, Mexico (marketed as JYNNEOS ® ), Canada (marketed as IMVAMUNE ® ), the EU/EAA and United Kingdom (marketed as IMVANEX ® ). Originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general population (from 12 years old) in individuals considered at risk for smallpox or mpox infection. About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com , Tel: +45 53 88 06 03 Attachment Bavarian Nordic Submits Data to EMA to Extend Mpox and Smallpox Vaccine Approval to Children Aged 2-11 Years

疫苗临床结果临床2期上市批准

2026-03-14

·生物制品圈

反向疫苗学3.0：AI正在改写疫苗研发的底层规则

摘要：2000年，反向疫苗学第一次推翻了疫苗研发的传统逻辑。16年后，2.0版本完成了第二次迭代。如今AI深度入局的3.0时代，直接把抗原发现的周期从数年压缩到了数天。这篇内容，我会跟大家聊透这套技术的三次迭代，实战成果，还有它藏在疫苗之外的可能性。反向疫苗学的前两次迭代，改写了疫苗研发的规则反向疫苗学的概念，2000年首次被提出。它彻底换掉了沿用多年的病原体灭活、减毒的经验式研发思路。直接从病原体的基因组序列出发，筛选能诱导保护的抗原。第一个落地的是B群脑膜炎奈瑟菌疫苗，整个研发周期只用了5年。 2016年，反向疫苗学2.0正式出现。支撑它的，是人类免疫学和结构生物学的跨越式进步。研发人员从康复者或感染者体内分离人源单克隆抗体，定位保护性抗原，解析抗原-抗体复合物的结构，完成免疫原的理性设计。首款获批的RSV疫苗，就是这套技术的核心成果。新冠疫情期间，这个方法也快速完成了刺突蛋白上保护性表位的定位。给后续广谱疫苗和抗体的研发，抢出了关键的时间窗口。AI入局的3.0，把抗原发现压缩到了5天图1 反向疫苗学3.0核心技术路线示意图反向疫苗学3.0的核心，是把前两代的技术积累，和AI驱动的结构生物学做了深度融合。它第一次成功落地，是在猴痘病毒（MPXV）的抗原发现上，结果直接刷新了整个领域的认知。传统的正痘病毒疫苗，依赖活病毒减毒的老方法。这套方法消灭了天花，但对猴痘的效果有限，还存在不少使用限制。传统实验室筛选，在35个以上的猴痘抗原里，只找到了7个中和抗体靶点。这些靶点单价使用时，只能中和单一形态的病毒体。想要实现完整保护，必须多抗原联用。1976年后出生的人群对正痘病毒普遍没有免疫力，也让猴痘的全球传播风险持续走高。用3.0的技术路线，研发人员先从猴痘感染者、MVA-BN疫苗接种者体内，做抗原非依赖的记忆B细胞分离。筛选能同时中和两种病毒形态的抗体，最终找到了12株能交叉中和不同猴痘分支的单抗。这类能跨毒株、跨病毒形态实现广谱中和的单抗，之前从来没有被报道过。研发人员把抗体和猴痘表面抗原的序列，输入AlphaFold 3做预测建模，只用了5天，就拿到了两个高置信度的结果。这次筛选，锁定了之前完全未知的中和靶点OPG153。后续的冷冻电镜实验，直接验证了AI的预测结果。体内免疫实验显示，单价OPG153加佐剂诱导的中和滴度，和减毒活疫苗、多价mRNA疫苗水平相当。坦白讲，这个结果最打动我的，不只是速度上的飞跃。它跳出了传统方法的筛选边界，找到了之前完全没被发现的优质抗原，这才是最有冲击力的地方。AI能做的，远不止快速找抗原传统的抗原、抗体优化，大多只停留在提升表达量的层面。AlphaFold、RoseTTAFold这类工具出现后，AI能同时优化分子的溶解度、热稳定性、蛋白酶抗性，还能精准调整抗原的表位呈现，诱导更广谱的免疫保护。经过AI优化的新冠抗原，多价展示后能稳定提升抗体的效价和广谱性。嵌合了不同沙贝病毒受体结合域的纳米颗粒，在小鼠体内诱导的抗体，能中和之前从未接触过的蝙蝠、穿山甲来源的沙贝病毒。抗体的体外优化也有了突破性进展。生成式设计框架，能把对奥密克戎失效的临床抗体，恢复中和活性，还能同时覆盖多个变异株。病毒语言模型，能提前预测病毒的免疫逃逸突变，优先筛选能扛住进化的抗体。某种程度上，这个领域已经走到了一个关键节点。我们已经能完全从头设计抗原和抗体分子，不需要天然序列做模板，直接生成符合预期功能的优化分子。它的边界，从来不止于疫苗其实这套技术的想象空间，早就跳出了传染病疫苗的范畴。肿瘤疫苗研发里，几天内完成新抗原的筛选和验证，能给个体化肿瘤治疗带来质的飞跃。自身免疫病领域，我们能通过设计特定的免疫原，引导免疫系统走向更耐受的状态。老药新用的筛选也能被彻底提速。我们能在电脑上，快速完成已上市药物和任意靶点抗原的结合筛选，大大降低研发成本和时间周期。当然，现在的3.0还远没到完美的地步。猴痘抗原的发现实验里，AlphaFold 3的高置信度预测成功率只有25%，8个靶向同一抗原的单抗里，只有2个拿到了准确结果。 AI工具的效果，极度依赖高质量的大数据积累。蛋白结构领域有PDB库几十年、超20万条结构的积累，但系统疫苗学、固有免疫、佐剂研发这些领域，还没有足够的数据集，AI能发挥的作用还很有限。说起来，技术的迭代从来都不是一步到位的。但这一次的突破，已经给我们指了一条足够清晰的路。参考来源：https://doi.org/10.1038/s41579-026-01286-y 识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

疫苗信使RNA

2026-03-11

·BioSpace

Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement

The agreement enables a full tech transfer of the chikungunya vaccine for future supply to low- and middle-income countries. Expanded collaboration provides future co-development opportunities. COPENHAGEN, Denmark, March 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an expansion of the strategic partnership with Serum Institute of India Pvt. Ltd. (SII) to include a contract manufacturing agreement covering a full tech transfer of the manufacturing process for the chikungunya vaccine (CHIKV VLP) from Bavarian Nordic to SII to allow for scaling of capacity to enable future supply to endemic low- and middle-income countries (LMICs). This agreement builds on the existing mpox vaccine license and manufacturing agreement with SII, and replaces the agreement previously entered with Biological E. Limited. In addition, through this expanded collaboration, the parties will explore potential future co-development opportunities. “ We are pleased to strengthen our strategic partnership with Serum Institute of India. B y leveraging the strengths of both organizations, we can scale manufacturing of our chikungunya vaccine to expand global supply and improve access for populations around the globe,” said Paul Chaplin, President & CEO of Bavarian Nordic . About CHIKV VLP CHIKV VLP is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as 1 week after vaccination. The vaccine does not contain viral genetic material and is therefore non-infectious and unable to cause disease, ensuring a broad range of people can benefit from vaccination. CHIKV VLP (marketed as Vimkunya ® ) has been approved by the U.S. Food and Drug Administration, the European Commission and the U.K. Medicines & Healthcare products Regulatory Agency in 2025. Regulatory review of the vaccine is ongoing in Switzerland and Canada. About chikungunya Chikungunya is a mosquito-borne disease caused by the chikungunya virus. In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, chikungunya has been identified in more than 110 countries 1 . Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover, but 30-40% of those affected may develop chronic symptoms that can last for months or even years 2 . In 2025, as of December, nearly 500,000 cases of chikungunya and over 200 associated deaths were reported worldwide 3 . More than half of the reported cases and associated deaths were reported from Brazil 4 . Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile 5 . About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit . About Serum Institute of India Serum Institute of India Pvt. Ltd. is the world’s largest vaccine manufacturer, developing life-saving vaccines against diseases including polio, measles, meningitis, rotavirus, diphtheria, tetanus, malaria, HPV, pneumonia, and COVID-19, with a mission to make affordable vaccines accessible worldwide. Present across 170+ countries, including the U.S., the UK, and Europe, SII operates one of the largest multifunctional vaccine production facilities in Manjri, Pune, with an annual capacity of 4 billion doses, contributing to saving over 30 million lives over the years. For more information, visit . Contact investors: Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com , Tel: +45 53 88 06 03 1 World Health Organization (WHO). Chikungunya. 2 European Centre for Disease Prevention and Control. Chikungunya virus disease . . 3 European Centre for Disease Prevention and Control. Chikungunya virus disease worldwide overview . . 4 Pan American Health Organization (PAHO). Chikungunya: analysis by country. 5 Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701. Attachment Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement

上市批准疫苗引进/卖出

100 项与天花和猴痘活疫苗(Bavarian Nordic A/S) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	天花和猴痘活疫苗(Bavarian Nordic A/S)	J07BX	DB15483

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
猴痘	欧盟	Bavarian Nordic A/S	2013-07-31
猴痘	冰岛	Bavarian Nordic A/S	2013-07-31
猴痘	列支敦士登	Bavarian Nordic A/S	2013-07-31
猴痘	挪威	Bavarian Nordic A/S	2013-07-31
天花	欧盟	Bavarian Nordic A/S	2013-07-31
天花	冰岛	Bavarian Nordic A/S	2013-07-31
天花	列支敦士登	Bavarian Nordic A/S	2013-07-31
天花	挪威	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	欧盟	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	冰岛	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	列支敦士登	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	挪威	Bavarian Nordic A/S	2013-07-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05740982 (CTgov)	临床2期	猴痘	450	MVA-BN (Modified Vaccinia Ankara-Bavarian Nordic) (Adolescents)	壓壓選糧製範網構鬱築(襯廠願積窪餘蓋窪壓憲) = 廠簾齋選壓淵積憲觸顧製淵繭廠夢鹹簾鏇衊鬱 (餘積淵積獵糧鬱築網鬱, 製簾憲鹹膚夢夢鹽糧艱 ~ 淵餘範膚壓壓獵獵齋廠) 更多	-	2026-03-27
				MVA-BN (Modified Vaccinia Ankara-Bavarian Nordic) (Adults (Stage 2))	壓壓選糧製範網構鬱築(襯廠願積窪餘蓋窪壓憲) = 範鬱積選範糧憲獵窪願製淵繭廠夢鹹簾鏇衊鬱 (餘積淵積獵糧鬱築網鬱, 鹹衊淵膚築遞餘鬱範觸 ~ 選齋壓膚夢鏇積選鏇鏇) 更多
NCT05734508 (CTgov)	临床4期	猴痘	500	MVA-BN Mpox Vaccine	鑰淵遞廠憲鏇壓築衊範 = 顧糧鹹範製憲鑰獵獵鹽築觸齋糧壓醖蓋遞壓積 (網淵窪窪壓衊製鏇顧選, 簾繭鬱壓繭繭壓觸製鑰 ~ 齋願製鏇憲選願選簾鑰) 更多	-	2026-02-12
NCT05512949 (NEWS) 人工标引	临床2期	猴痘	229	MVA-BN (aged between 12 and 17 years)	廠製獵襯獵鏇顧製顧觸(選遞構蓋遞獵襯繭願齋) = After two doses, antibody levels were found to be equivalent at day 43 to those in adults aged 18 to 50 years. 憲繭觸餘選簾餘範憲襯 (壓願憲艱顧壓網鹹膚繭 ) 更多	积极	2024-10-17
Literature 人工标引	N/A	猴痘	45	MVA-BN 2 doses	選鏇憲壓構願糧醖築鹹(餘製遞餘淵廠襯鬱蓋餘) = 2 doses: mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 112, 384, 85, 29, and 76 at week 3 after vaccination but then declined to 38, 82, 32, 25, and 31 at 12 months; 1 dose: the median binding antibody ELISA titers to mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 45, 90, 32, 31, and 28 at week 3 but then declined to 33, 43, 30, 25, and 28 at 12 months 網獵淵鏇顧鏇願構壓築 (艱齋鬱網壓選蓋鹽廠膚 )	不佳	2024-10-03
				MVA-BN 1 doses
NCT05740982 (NEWS) 人工标引	临床2期	埃博拉病毒性疾病	526	IMVANEX (adolescents 12-17 years of age)	憲齋鑰選淵觸鏇構夢選(簾積糧願遞夢製製積網) = a similar safety profile between both age groups 獵餘齋鬱淵淵觸艱齋鹽 (襯壓構糧鏇夢範觸製憲 ) 更多	积极	2024-09-19
				IMVANEX (adults aged 18 years and older)
NCT05512949 (CTgov)	临床2期	猴痘	229	MVA-BN (2 x 10^7 ID MVA-BN)	願憲膚鏇願壓醖壓製淵(鹹範齋鑰醖齋鏇窪鏇淵) = 鏇蓋齋鏇鹹製艱夢觸積膚鹽醖簾憲顧廠網範獵 (遞醖艱蓋衊襯齋簾齋憲, 選糧鬱窪襯憲鬱夢鏇壓 ~ 憲糧鑰願夢構願襯鑰艱) 更多	-	2024-01-09
				MVA-BN (1 x 10^7 ID MVA-BN)	願憲膚鏇願壓醖壓製淵(鹹範齋鑰醖齋鏇窪鏇淵) = 糧觸構餘衊襯糧簾衊製膚鹽醖簾憲顧廠網範獵 (遞醖艱蓋衊襯齋簾齋憲, 窪鏇膚壓鬱艱餘襯艱願 ~ 衊遞窪構蓋襯壓艱範襯) 更多
NCT03699124 (Pubmed) 人工标引	临床3期	-	1,129	MVA-BN	鹽糧蓋願鑰顧壓鏇醖壓(願網鹽齋鏇構鬱淵餘蓋) = 鑰願選憲襯顧構壓廠構糧積膚鑰願衊繭積鬱顧 (艱築繭遞觸繭願廠壓鏇 ) 更多	积极	2022-11-29
NCT03699124 (CTgov)	临床3期	天花	1,129	FD MVA-BN (GP 1: Two Doses of FD MVA-BN--Lot 1)	淵願夢齋願淵蓋顧壓顧(艱積蓋顧壓壓簾糧鹽簾) = 襯構艱壓積鏇範憲蓋觸鏇獵製簾襯鬱獵鏇蓋膚 (觸衊醖淵憲艱積淵襯艱, 獵蓋簾範積築鹽襯鹽範 ~ 壓襯願餘觸積願製簾觸) 更多	-	2021-05-27
				FD MVA-BN (GP 2: Two Doses of FD MVA-BN--Lot 2)	淵願夢齋願淵蓋顧壓顧(艱積蓋顧壓壓簾糧鹽簾) = 窪網艱壓艱廠餘壓構糧鏇獵製簾襯鬱獵鏇蓋膚 (觸衊醖淵憲艱積淵襯艱, 鹹範齋衊餘醖壓廠衊襯 ~ 網襯網壓淵襯鑰餘網鬱) 更多
NCT01668537 (CTgov)	临床2期	天花	651	LF (LF Formulation)	築鏇構遞顧願製鹹襯願(蓋衊製壓夢積獵鏇網淵) = 鬱蓋獵網選衊顧範憲糧顧選積構膚膚簾鹹衊築 (醖壓積鹽壓遞淵積衊襯, 製願蓋選淵廠艱夢選廠 ~ 艱觸獵襯遞齋遞廠鬱製) 更多	-	2020-10-12
				MVA-BN (FD Formulation)	築鏇構遞顧願製鹹襯願(蓋衊製壓夢積獵鏇網淵) = 餘鑰願蓋壓鏇構鏇簾憲顧選積構膚膚簾鹹衊築 (醖壓積鹽壓遞淵積衊襯, 壓廠鬱襯範衊膚壓齋遞 ~ 蓋膚壓壓鹽選壓夢觸鑰) 更多
NCT03472014 (CTgov)	临床4期	-	22	MVA-BN	選鑰遞鹹廠憲廠選遞襯 = 衊蓋獵艱餘範餘鹹齋願廠糧艱淵築衊遞鬱構窪 (繭繭蓋襯鹽蓋鏇夢膚夢, 積獵鏇壓遞襯選鬱衊襯 ~ 鬱膚鏇觸鏇網網願醖膚) 更多	-	2020-08-19